Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025
Lexicon Pharmaceuticals (NASDAQ:LXRX) announced it will present new preclinical data for pilavapadin at the NeuPSIG 2025 conference in Berlin. The research demonstrates the drug's effectiveness in reducing neuropathic pain in preclinical models of chemotherapy-induced peripheral neuropathy (CIPN) and multiple sclerosis (MS).
The findings emphasize the importance of inhibiting pilavapadin's novel target, AAK1, for pain signaling modulation. The company will also present a poster on the study design of PROGRESS, a Phase 2b dose-ranging study of pilavapadin in diabetic peripheral neuropathic pain (DPNP). The presentations suggest potential expansion of pilavapadin's applications beyond its current focus on DPNP.
Lexicon Pharmaceuticals (NASDAQ:LXRX) ha annunciato che presenterà nuovi dati preclinici su pilavapadin alla conferenza NeuPSIG 2025 a Berlino. La ricerca mostra l'efficacia del farmaco nel ridurre il dolore neuropatico in modelli preclinici di neuropatia periferica indotta da chemioterapia (CIPN) e di sclerosi multipla (SM).
I risultati sottolineano l'importanza di inibire il nuovo bersaglio di pilavapadin, AAK1, per modulare la trasmissione del dolore. L'azienda presenterà inoltre un poster sul disegno dello studio PROGRESS, uno studio di fase 2b con range di dosi di pilavapadin nel dolore neuropatico periferico diabetico (DPNP). Le presentazioni suggeriscono la possibilità di ampliare le indicazioni di pilavapadin oltre l'attuale focus sul DPNP.
Lexicon Pharmaceuticals (NASDAQ:LXRX) anunció que presentará nuevos datos preclínicos sobre pilavapadin en la conferencia NeuPSIG 2025 en Berlín. La investigación demuestra la eficacia del fármaco para reducir el dolor neuropático en modelos preclínicos de neuropatía periférica inducida por quimioterapia (CIPN) y de esclerosis múltiple (EM).
Los hallazgos ponen de relieve la importancia de inhibir el nuevo objetivo de pilavapadin, AAK1, para modular la señalización del dolor. La compañía también presentará un póster sobre el diseño del estudio PROGRESS, un ensayo de fase 2b con rango de dosis de pilavapadin en dolor neuropático periférico diabético (DPNP). Las presentaciones sugieren la posibilidad de ampliar las aplicaciones de pilavapadin más allá de su enfoque actual en DPNP.
Lexicon Pharmaceuticals (NASDAQ:LXRX)는 2025년 베를린에서 열리는 NeuPSIG 학회에서 pilavapadin에 대한 새로운 전임상 데이터를 발표할 예정이라고 밝혔다. 연구는 이 약물이 항암화학요법 유발 말초신경병증(CIPN)과 다발성 경화증(MS) 전임상 모델에서 신경병성 통증을 감소시키는 효과가 있음을 보여준다.
이 결과는 통증 신호 조절을 위해 pilavapadin의 새로운 표적 AAK1을 억제하는 것이 중요함을 강조한다. 회사는 또한 제2b상 용량 탐색 연구인 PROGRESS의 연구 설계에 관한 포스터를 발표할 예정이다. 발표들은 pilavapadin의 적응증이 현재의 DPNP 중심에서 확장될 가능성을 시사한다.
Lexicon Pharmaceuticals (NASDAQ:LXRX) a annoncé qu'elle présentera de nouvelles données précliniques sur pilavapadin lors de la conférence NeuPSIG 2025 à Berlin. Les recherches montrent l'efficacité du médicament pour réduire la douleur neuropathique dans des modèles précliniques de neuropathie périphérique induite par la chimiothérapie (CIPN) et de sclérose en plaques (SEP).
Les résultats soulignent l'importance d'inhiber la nouvelle cible de pilavapadin, AAK1, pour moduler la transmission de la douleur. La société présentera également un poster sur le plan de l'étude PROGRESS, un essai de phase 2b d'évaluation des doses de pilavapadin dans la douleur neuropathique périphérique diabétique (DPNP). Les présentations suggèrent un potentiel d'élargissement des indications de pilavapadin au‑delà de son focus actuel sur le DPNP.
Lexicon Pharmaceuticals (NASDAQ:LXRX) gab bekannt, neue präklinische Daten zu pilavapadin auf der NeuPSIG 2025 in Berlin vorzustellen. Die Forschung zeigt, dass das Medikament in präklinischen Modellen der chemotherapieinduzierten peripheren Neuropathie (CIPN) und der Multiplen Sklerose (MS) wirksam zur Verringerung neuropathischer Schmerzen ist.
Die Ergebnisse heben hervor, wie wichtig die Hemmung des neuen Targets von pilavapadin, AAK1, zur Modulation der Schmerzsignalgebung ist. Das Unternehmen wird außerdem ein Poster zum Studiendesign von PROGRESS präsentieren, einer Phase-2b-Dosisfindungsstudie von pilavapadin bei diabetischer peripherer Neuropathie-Schmerz (DPNP). Die Präsentationen deuten auf eine mögliche Ausweitung der Anwendung von pilavapadin über den aktuellen Fokus auf DPNP hinaus hin.
- None.
- None.
THE WOODLANDS, Texas, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Company will present new data demonstrating the reduction of neuropathic pain by pilavapadin in preclinical models of chemotherapy-induced peripheral neuropathy (CIPN) and multiple sclerosis (MS) at the 9th International Congress on Neuropathic Pain - (NeuPSIG) 2025. The findings highlight the relevance of inhibiting pilavapadin’s novel target, AAK1, for the modulation of pain signaling. The conference is being held September 4 – 6, 2025 in Berlin, Germany.
Presentation details:
- Poster: LX9211, a Novel AAK1 Inhibitor, Alleviates Pain in Preclinical Models of Chemotherapy-induced Neuropathic Pain and Multiple Sclerosis
- Date: Saturday, September 6, 2025
- Time: 8:30 a.m. – 6:00 p.m. CEST
- Location: Exhibition Poster Area
- Presenter: Suma Gopinathan, Senior Vice President, Discovery, Lexicon Pharmaceuticals
“We are encouraged by the promising results with pilavapadin in preclinical models of CIPN and MS, which highlight the potential of pilavapadin in additional neuropathic pain indications beyond diabetic peripheral neuropathic pain (DPNP),” said Suma Gopinathan, Senior Vice President of Discovery for Lexicon. “These data build upon the robust body of evidence supporting AAK1 inhibition as a powerful target for diverse neuropathic pain conditions.”
Separately, Lexicon will also present a poster entitled “Study Design and Rationale of PROGRESS: Pilavapadin in a Phase 2b, Dose-ranging, Double-blind, Placebo-controlled Study in Diabetic Peripheral Neuropathic Pain.”
About Pilavapadin
Discovered using Lexicon’s unique approach to gene science, pilavapadin is a potent, once-daily, orally delivered, selective, investigational small molecule inhibitor of AAK1, a novel target for neuropathic pain which inhibits reuptake and recycling of neurotransmitters involved in pain signaling without affecting opiate pathways. Lexicon identified AAK1 in its target discovery efforts as a promising approach for the treatment of neuropathic pain. Preclinical studies of pilavapadin demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain without affecting opiate pathways.
Pilavapadin has received Fast Track designation from the U.S. Food and Drug Administration for development in diabetic peripheral neuropathic pain (DPNP).
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, metabolism and other indications. For additional information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of its other drug candidates, including pilavapadin. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
FAQ
What new data will Lexicon Pharmaceuticals (LXRX) present at NeuPSIG 2025?
What is pilavapadin's mechanism of action for pain treatment?
When and where will Lexicon's (LXRX) NeuPSIG 2025 presentation take place?
What is the PROGRESS study that Lexicon Pharmaceuticals will present at NeuPSIG 2025?
What potential applications does pilavapadin have beyond DPNP?
